The findings represent the first known successful regeneration of skin and hair in full-thickness swine wound models, the standard animal model for human skin. The Company expects to initiate a human clinical trial evaluating the autologous homologous SkinTE™ construct in the third quarter of 2017.

In pre-clinical models of full-thickness burns and wounds, SkinTE™ demonstrated scar-less healing, hair follicle growth, immediate complete wound coverage, and the progressive regeneration of all skin layers including epidermis, dermis and hypodermal layers (www.polarityte.com/products/skinte). The SkinTE™ product, which utilizes the subject's own skin, is prepared and used to treat the wound in less than 24 hours.

* A regenerative medicine company with a revolutionary proprietary platform technology developing products to regenerate fully functional tissue across a wide spectrum of tissues – skin, bone, muscle, cartilage, nerve, liver, and more
* The proprietary platform technology provides a springboard for repeated product development targeting independent multibillion dollar markets – wounds, bone (trauma, spinal fusion, craniofacial, dental), osteoarthritis, etc.